



## Measure Information

This document contains the information submitted by measure developers/stewards, but is organized according to NQF's measure evaluation criteria and process. The item numbers refer to those in the submission form but may be in a slightly different order here. In general, the item numbers also reference the related criteria (e.g., item 1b.1 relates to subcriterion 1b).

### Brief Measure Information

**NQF #: 2526**

**De.2. Measure Title:** Gout: Anti-inflammatory Prophylaxis with ULT Therapy (Not Recommended for eMeasure Trial Approval)

**Co.1.1. Measure Steward:** AMERICAN COLLEGE OF RHEUMATOLOGY

**De.3. Brief Description of Measure:** Percentage of patients aged 18 and older with a diagnosis of gout initiated on urate-lowering therapy (ULT), who are receiving concomitant anti-inflammatory prophylaxis (defined as low dose colchicine, non-steroid anti-inflammatory drug (NSAID) or glucocorticoid)

**1b.1. Developer Rationale:** After starting urate lowering therapy, there is an increased rate of acute gout flares for several months. For the recent randomized control trials, where prophylaxis was continued for only 8 weeks, 40% of patients flared upon cessation of prophylaxis, whereas if prophylaxis was continued for 6 months, only 5% of patients flared [2]. In a small randomized control trial using colchicine vs. placebo, patients assigned to colchicine had fewer flares at 0-3 and 3-6 months (0.57 and 0 flares) vs. patients assigned to placebo (1.91, 1.05 flares), both differences statistically different [3].

Forty-three subjects were studied. Subjects treated with colchicine experienced fewer total flares (0.52 vs 2.91,  $p = 0.008$ ), fewer flares from 0 to 3 months (0.57 vs 1.91,  $p = 0.022$ ), fewer flares 3-6 months (0 vs 1.05,  $p = 0.033$ ), less severe flares as reported on VAS (3.64 vs 5.08,  $p = 0.018$ ), and fewer recurrent gout flares ( $p = 0.001$ ). Colchicine was well tolerated.

[2] Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of uratelowering therapy: analysis of data from three phase III trials. Clin Ther 2010;32:2386–97.

[3] Borstad GC, Bryant LR, Abel MP, Scroogie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429–32.

**S.4. Numerator Statement:** Patients prescribed anti-inflammatory prophylaxis (including low-dose colchicine, non-steroidal anti-inflammatory (NSAID) or glucocorticoid)

**S.7. Denominator Statement:** Patients aged 18 and older with an established gout diagnosis initiating urate lowering (ULT) therapy

**S.10. Denominator Exclusions:** None

**De.1. Measure Type:** Process

**S.23. Data Source:** Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry

**S.26. Level of Analysis:** Clinician : Individual

**IF Endorsement Maintenance – Original Endorsement Date: Most Recent Endorsement Date:**

**IF this measure is included in a composite, NQF Composite#/title:**

**IF this measure is paired/grouped, NQF#/title:**

**De.4. IF PAIRED/GROUPED, what is the reason this measure must be reported with other measures to appropriately interpret results?**

### 1. Evidence, Performance Gap, Priority – Importance to Measure and Report

Extent to which the specific measure focus is evidence-based, important to making significant gains in healthcare quality, and

improving health outcomes for a specific high-priority (high-impact) aspect of healthcare where there is variation in or overall less-than-optimal performance. **Measures must be judged to meet all subcriteria to pass this criterion and be evaluated against the remaining criteria.**

**1a. Evidence to Support the Measure Focus – See attached Evidence Submission Form**

[Gout\\_Anti-inflammatory\\_Prophylaxis\\_with\\_ULT\\_Therapy\\_Evidence\\_Form\\_Final.docx](#)

**1b. Performance Gap**

Demonstration of quality problems and opportunity for improvement, i.e., data demonstrating:

- considerable variation, or overall less-than-optimal performance, in the quality of care across providers; and/or
- disparities in care across population groups.

**1b.1. Briefly explain the rationale for this measure (e.g., the benefits or improvements in quality envisioned by use of this measure)**

After starting urate lowering therapy, there is an increased rate of acute gout flares for several months.

For the recent randomized control trials, where prophylaxis was continued for only 8 weeks, 40% of patients flared upon cessation of prophylaxis, whereas if prophylaxis was continued for 6 months, only 5% of patients flared [2].

In a small randomized control trial using colchicine vs. placebo, patients assigned to colchicine had fewer flares at 0-3 and 3-6 months (0.57 and 0 flares) vs. patients assigned to placebo (1.91, 1.05 flares), both differences statistically different [3].

Forty-three subjects were studied. Subjects treated with colchicine experienced fewer total flares (0.52 vs 2.91,  $p = 0.008$ ), fewer flares from 0 to 3 months (0.57 vs 1.91,  $p = 0.022$ ), fewer flares 3-6 months (0 vs 1.05,  $p = 0.033$ ), less severe flares as reported on VAS (3.64 vs 5.08,  $p = 0.018$ ), and fewer recurrent gout flares ( $p = 0.001$ ). Colchicine was well tolerated.

[2] Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of uratelowering therapy: analysis of data from three phase III trials. Clin Ther 2010;32:2386–97.

[3] Borstad GC, Bryant LR, Abel MP, Scroogie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429–32.

**1b.2. Provide performance scores on the measure as specified (current and over time) at the specified level of analysis.** (This is required for endorsement maintenance. Include mean, std dev, min, max, interquartile range, scores by decile. Describe the data source including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included.) This information also will be used to address the subcriterion on improvement (4b.1) under Usability and Use.

N/A

**1b.3. If no or limited performance data on the measure as specified is reported in 1b2, then provide a summary of data from the literature that indicates opportunity for improvement or overall less than optimal performance on the specific focus of measurement.**

Among a cohort of 297 Veterans receiving allopurinol, only 10% received colchicine prophylaxis.

Singh, J. A., J. S. Hodges, et al. (2009). Ann Rheum Dis 68(8): 1265-1270

**1b.4. Provide disparities data from the measure as specified (current and over time) by population group, e.g., by race/ethnicity, gender, age, insurance status, socioeconomic status, and/or disability.** (This is required for endorsement maintenance. Describe the data source including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities include.) This information also will be used to address the subcriterion on improvement (4b.1) under Usability and Use.

Since this is a newly proposed e-measure, no disparities data from the measure as specified is yet available.

**1b.5. If no or limited data on disparities from the measure as specified is reported in 1b4, then provide a summary of data from the literature that addresses disparities in care on the specific focus of measurement. Include citations.**

Since this is a newly proposed e-measure, no disparities data from the measure as specified is yet available. However, a recent review highlighted that there is a higher prevalence of gout among African-Americans and poorer quality of care delivered to this group. The prevalence of gout in men is much higher than women, until post-menopausal status when rates for gout increase markedly among women.

Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013 Feb;15(2):307.

**1c. High Priority** (previously referred to as High Impact)

The measure addresses:

- a specific national health goal/priority identified by DHHS or the National Priorities Partnership convened by NQF; OR
- a demonstrated high-priority (high-impact) aspect of healthcare (e.g., affects large numbers of patients and/or has a substantial impact for a smaller population; leading cause of morbidity/mortality; high resource use (current and/or future); severity of illness; and severity of patient/societal consequences of poor quality).

**1c.1. Demonstrated high priority aspect of healthcare**

Affects large numbers, A leading cause of morbidity/mortality, High resource use, Patient/societal consequences of poor quality

**1c.2. If Other:**

**1c.3. Provide epidemiologic or resource use data that demonstrates the measure addresses a high priority aspect of healthcare.**

List citations in 1c.4.

Gout affects 8 million Americans. Among gout patients who work, they miss on an average of 5 days more of work per year than patients without who are working without a gout diagnosis. (Wertheimer 2013). The same study reports that gout patients cost \$3000 per year more than non-gout patients with an estimated cost in the “tens of billions of dollars”. Acute flares consume medical dollars in terms of emergency room and physician visits, treatment related costs and lost work days. Chronic gout patients suffer from morbidity of the disease and many comorbid metabolic syndrome conditions.

**1c.4. Citations for data demonstrating high priority provided in 1a.3**

Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp. 2013 Dec;75:1-4.

**1c.5. If a PRO-PM (e.g. HRQoL/functional status, symptom/burden, experience with care, health-related behaviors), provide evidence that the target population values the measured PRO and finds it meaningful. (Describe how and from whom their input was obtained.)**

N/A

## 2. Reliability and Validity—Scientific Acceptability of Measure Properties

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. **Measures must be judged to meet the subcriteria for both reliability and validity to pass this criterion and be evaluated against the remaining criteria.**

**2a.1. Specifications** The measure is well defined and precisely specified so it can be implemented consistently within and across organizations and allows for comparability. eMeasures should be specified in the Health Quality Measures Format (HQMF) and the Quality Data Model (QDM).

**De.5. Subject/Topic Area** (check all the areas that apply):

Musculoskeletal

**De.6. Cross Cutting Areas** (check all the areas that apply):

**S.1. Measure-specific Web Page** (Provide a URL link to a web page specific for this measure that contains current detailed specifications including code lists, risk model details, and supplemental materials. Do not enter a URL linking to a home page or to general information.)

**S.2a. If this is an eMeasure**, HQMF specifications must be attached. Attach the output from the eMeasure authoring tool (MAT) - if the MAT was not used, contact staff. (Use the specification fields in this online form for the plain-language description of the specifications)

Attachment Attachment: 2526\_GOUTAntiInflammatory\_Artifacts.zip

**S.2b. Data Dictionary, Code Table, or Value Sets** (and risk model codes and coefficients when applicable) must be attached. (Excel or

csv file in the suggested format preferred - if not, contact staff)

Attachment Attachment: 2526\_AntiInflammatory\_Mon\_Apr\_21\_11.12.51\_CDT\_2014-1-.xls

**S.3. For endorsement maintenance**, please briefly describe any changes to the measure specifications since last endorsement date and explain the reasons.

N/A

**S.4. Numerator Statement** (Brief, narrative description of the measure focus or what is being measured about the target population, i.e., cases from the target population with the target process, condition, event, or outcome)  
IF an OUTCOME MEASURE, state the outcome being measured. Calculation of the risk-adjusted outcome should be described in the calculation algorithm.

Patients prescribed anti-inflammatory prophylaxis (including low-dose colchicine, non-steroidal anti-inflammatory (NSAID) or glucocorticoid)

**S.5. Time Period for Data** (What is the time period in which data will be aggregated for the measure, e.g., 12 mo, 3 years, look back to August for flu vaccination? Note if there are different time periods for the numerator and denominator.)

A 12-month reporting period is anticipated for this measure.

**S.6. Numerator Details** (All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, specific data collection items/responses, code/value sets – Note: lists of individual codes with descriptors that exceed 1 page should be provided in an Excel or csv file in required format at S.2b)  
IF an OUTCOME MEASURE, describe how the observed outcome is identified/counted. Calculation of the risk-adjusted outcome should be described in the calculation algorithm.

Patients prescribed anti-inflammatory prophylaxis (including low-dose colchicine, non-steroidal anti-inflammatory (NSAID) or glucocorticoid)

**S.7. Denominator Statement** (Brief, narrative description of the target population being measured)

Patients aged 18 and older with an established gout diagnosis initiating urate lowering (ULT) therapy

**S.8. Target Population Category** (Check all the populations for which the measure is specified and tested if any):

**S.9. Denominator Details** (All information required to identify and calculate the target population/denominator such as definitions, specific data collection items/responses, code/value sets – Note: lists of individual codes with descriptors that exceed 1 page should be provided in an Excel or csv file in required format at S.2b)

Patients aged 18 and older with an established gout diagnosis initiating urate lowering (ULT) therapy

**S.10. Denominator Exclusions** (Brief narrative description of exclusions from the target population)

None

**S.11. Denominator Exclusion Details** (All information required to identify and calculate exclusions from the denominator such as definitions, specific data collection items/responses, code/value sets – Note: lists of individual codes with descriptors that exceed 1 page should be provided in an Excel or csv file in required format at S.2b)

None

**S.12. Stratification Details/Variables** (All information required to stratify the measure results including the stratification variables, definitions, specific data collection items/responses, code/value sets – Note: lists of individual codes with descriptors that exceed 1 page should be provided in an Excel or csv file in required format with at S.2b)

**S.13. Risk Adjustment Type** (Select type. Provide specifications for risk stratification in S.12 and for statistical model in S.14-15)

If other:

**S.14. Identify the statistical risk model method and variables** (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development and testing should be addressed with measure testing under Scientific Acceptability)

**S.15. Detailed risk model specifications** (must be in attached data dictionary/code list Excel or csv file. Also indicate if available at measure-specific URL identified in S.1.)

Note: Risk model details (including coefficients, equations, codes with descriptors, definitions), should be provided on a separate worksheet in the suggested format in the Excel or csv file with data dictionary/code lists at S.2b.

**S.15a. Detailed risk model specifications** (if not provided in excel or csv file at S.2b)

**S.16. Type of score:**

If other:

**S.17. Interpretation of Score** (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score)

**S.18. Calculation Algorithm/Measure Logic** (Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.)

**S.19. Calculation Algorithm/Measure Logic Diagram URL or Attachment** (You also may provide a diagram of the Calculation Algorithm/Measure Logic described above at measure-specific Web page URL identified in S.1 OR in attached appendix at A.1)

**S.20. Sampling** (If measure is based on a sample, provide instructions for obtaining the sample and guidance on minimum sample size.)

IF a PRO-PM, identify whether (and how) proxy responses are allowed.

**S.21. Survey/Patient-reported data** (If measure is based on a survey, provide instructions for conducting the survey and guidance on minimum response rate.)

IF a PRO-PM, specify calculation of response rates to be reported with performance measure results.

**S.22. Missing data** (specify how missing data are handled, e.g., imputation, delete case.)

Required for Composites and PRO-PMs.

Missing data is not anticipated for this measure. We are submitting this measure for consideration for time-limited endorsement only. When we test these measures, we will identify and address any issues related to missing data.

**S.23. Data Source** (Check ONLY the sources for which the measure is SPECIFIED AND TESTED).

If other, please describe in S.24.

Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry

**S.24. Data Source or Collection Instrument** (Identify the specific data source/data collection instrument e.g. name of database, clinical registry, collection instrument, etc.)

IF a PRO-PM, identify the specific PROM(s); and standard methods, modes, and languages of administration.

The ACR plan for measure testing includes testing data from at least 3 different types of EHRs, from at least 3 different sites, using a

[standardized data collection form.](#)

**S.25. Data Source or Collection Instrument** (available at measure-specific Web page URL identified in S.1 OR in attached appendix at A.1)

[No data collection instrument provided](#)

**S.26. Level of Analysis** (Check ONLY the levels of analysis for which the measure is SPECIFIED AND TESTED)

[Clinician : Individual](#)

**S.27. Care Setting** (Check ONLY the settings for which the measure is SPECIFIED AND TESTED)

[Ambulatory Care : Clinician Office/Clinic](#)

If other:

**S.28. COMPOSITE Performance Measure** - Additional Specifications (Use this section as needed for aggregation and weighting rules, or calculation of individual performance measures if not individually endorsed.)

**2a. Reliability** – See attached Measure Testing Submission Form

**2b. Validity** – See attached Measure Testing Submission Form

### 3. Feasibility

Extent to which the specifications including measure logic, require data that are readily available or could be captured without undue burden and can be implemented for performance measurement.

#### 3a. Byproduct of Care Processes

For clinical measures, the required data elements are routinely generated and used during care delivery (e.g., blood pressure, lab test, diagnosis, medication order).

##### 3a.1. Data Elements Generated as Byproduct of Care Processes.

[Generated or collected by and used by healthcare personnel during the provision of care \(e.g., blood pressure, lab value, diagnosis, depression score\), Coded by someone other than person obtaining original information \(e.g., DRG, ICD-9 codes on claims\)](#)

If other:

#### 3b. Electronic Sources

The required data elements are available in electronic health records or other electronic sources. If the required data are not in electronic health records or existing electronic sources, a credible, near-term path to electronic collection is specified.

**3b.1. To what extent are the specified data elements available electronically in defined fields?** (i.e., data elements that are needed to compute the performance measure score are in defined, computer-readable fields)

[ALL data elements are in defined fields in a combination of electronic sources](#)

**3b.2. If ALL the data elements needed to compute the performance measure score are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources.**

**3b.3. If this is an eMeasure, provide a summary of the feasibility assessment in an attached file or make available at a measure-specific URL.**

[Attachment Attachment: Gout\\_Measures\\_Feasibility\\_Assessment\\_Summary\\_for\\_NQF\\_Submission-635336920907687557.xlsx](#)

#### 3c. Data Collection Strategy

Demonstration that the data collection strategy (e.g., source, timing, frequency, sampling, patient confidentiality, costs associated with fees/licensing of proprietary measures) can be implemented (e.g., already in operational use, or testing demonstrates that it is ready to put into operational use). For eMeasures, a feasibility assessment addresses the data elements and measure logic and demonstrates the eMeasure can be implemented or feasibility concerns can be adequately addressed.

**3c.1. Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues.**  
**IF a PRO-PM, consider implications for both individuals providing PROM data (patients, service recipients, respondents) and those whose performance is being measured.**  
 This measure is being submitted for time-limited endorsement and has not been tested. Plans are in place for a 2014 testing project.

**3c.2. Describe any fees, licensing, or other requirements to use any aspect of the measure as specified (e.g., value/code set, risk model, programming code, algorithm).**

#### 4. Usability and Use

Extent to which potential audiences (e.g., consumers, purchasers, providers, policy makers) are using or could use performance results for both accountability and performance improvement to achieve the goal of high-quality, efficient healthcare for individuals or populations.

##### 4a. Accountability and Transparency

Performance results are used in at least one accountability application within three years after initial endorsement and are publicly reported within six years after initial endorsement (or the data on performance results are available). If not in use at the time of initial endorsement, then a credible plan for implementation within the specified timeframes is provided.

##### 4.1. Current and Planned Use

*NQF-endorsed measures are expected to be used in at least one accountability application within 3 years and publicly reported within 6 years of initial endorsement in addition to performance improvement.*

Planned	Current Use (for current use provide URL)
Public Reporting	
Payment Program	
Quality Improvement with Benchmarking (external benchmarking to multiple organizations)	
Quality Improvement (Internal to the specific organization)	
Not in use	

##### 4a.1. For each CURRENT use, checked above, provide:

- Name of program and sponsor
- Purpose
- Geographic area and number and percentage of accountable entities and patients included

N/A

**4a.2. If not currently publicly reported OR used in at least one other accountability application (e.g., payment program, certification, licensing) what are the reasons? (e.g., Do policies or actions of the developer/steward or accountable entities restrict access to performance results or impede implementation?)**

Measure is still being tested.



**4a.3. If not currently publicly reported OR used in at least one other accountability application, provide a credible plan for implementation within the expected timeframes -- any accountability application within 3 years and publicly reported within 6 years of initial endorsement.** (*Credible plan includes the specific program, purpose, intended audience, and timeline for implementing the measure within the specified timeframes. A plan for accountability applications addresses mechanisms for data aggregation and reporting.*)

Specifications for this measure will be finalized and full field testing will be completed in the next 12 months, at which time the ACR will seek full NQF endorsement. In addition, the ACR will implement these measures into its EHR-enabled registry this year, at which time they will be part of the registry's plan for public reporting.

#### 4b. Improvement

Progress toward achieving the goal of high-quality, efficient healthcare for individuals or populations is demonstrated. If not in use for performance improvement at the time of initial endorsement, then a credible rationale describes how the performance results could be used to further the goal of high-quality, efficient healthcare for individuals or populations.

##### 4b.1. Progress on Improvement. (Not required for initial endorsement unless available.)

Performance results on this measure (current and over time) should be provided in 1b.2 and 1b.4. Discuss:

- Progress (trends in performance results, number and percentage of people receiving high-quality healthcare)
- Geographic area and number and percentage of accountable entities and patients included

The ACR is seeking time-limited endorsement for this measure; therefore, this does not apply.

**4b.2. If no improvement was demonstrated, what are the reasons? If not in use for performance improvement at the time of initial endorsement, provide a credible rationale that describes how the performance results could be used to further the goal of high-quality, efficient healthcare for individuals or populations.**

The ACR is seeking time-limited endorsement for this measure; therefore, this does not apply.

#### 4c. Unintended Consequences

The benefits of the performance measure in facilitating progress toward achieving high-quality, efficient healthcare for individuals or populations outweigh evidence of unintended negative consequences to individuals or populations (if such evidence exists).

**4c.1. Were any unintended negative consequences to individuals or populations identified during testing; OR has evidence of unintended negative consequences to individuals or populations been reported since implementation? If so, identify the negative unintended consequences and describe how benefits outweigh them or actions taken to mitigate them.**

The ACR is seeking time-limited endorsement for this measure; therefore, this does not apply.

## 5. Comparison to Related or Competing Measures

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure.

#### 5. Relation to Other NQF-endorsed Measures

Are there related measures (conceptually, either same measure focus or target population) or competing measures (conceptually both the same measure focus and same target population)? If yes, list the NQF # and title of all related and/or competing measures.

No

##### 5.1a. List of related or competing measures (selected from NQF-endorsed measures)

**5.1b. If related or competing measures are not NQF endorsed please indicate measure title and steward.**

#### 5a. Harmonization

The measure specifications are harmonized with related measures;

**OR**

The differences in specifications are justified



**5a.1. If this measure conceptually addresses EITHER the same measure focus OR the same target population as NQF-endorsed measure(s):**

**Are the measure specifications completely harmonized?**

**5a.2. If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden.**

**5b. Competing Measures**

The measure is superior to competing measures (e.g., is a more valid or efficient way to measure);

**OR**

Multiple measures are justified.

**5b.1. If this measure conceptually addresses both the same measure focus and the same target population as NQF-endorsed measure(s):**

**Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible.)**

**Appendix**

**A.1 Supplemental materials may be provided in an appendix.** All supplemental materials (such as data collection instrument or methodology reports) should be organized in one file with a table of contents or bookmarks. If material pertains to a specific submission form number, that should be indicated. Requested information should be provided in the submission form and required attachments. There is no guarantee that supplemental materials will be reviewed.

**Attachment:**

**Contact Information**

**Co.1 Measure Steward (Intellectual Property Owner):** AMERICAN COLLEGE OF RHEUMATOLOGY

**Co.2 Point of Contact:** RACHEL, MY, RMYSLINSKI@RHEUMATOLOGY.ORG, 404-633-3777-824

**Co.3 Measure Developer if different from Measure Steward:** AMERICAN COLLEGE OF RHEUMATOLOGY

**Co.4 Point of Contact:** RACHEL, MY, RMYSLINSKI@RHEUMATOLOGY.ORG, 404-633-3777-824

**Additional Information**

**Ad.1 Workgroup/Expert Panel involved in measure development**

**Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.**

John Fitzgerald, MD, Univ of California, Los Angeles (UCLA) (workgroup/panel chair)

Puja Khanna, MD, MPH, University of Michigan (workgroup member)

Ted Mikuls, MD, MSPH, University of Nebraska (workgroup member)

Tuhina Neogi, MD, PhD, Boston University (workgroup member)

Mark Robbins, MD, Harvard Vanguard Medical Associates (workgroup member)

Jasvinder Singh, MD, MPH, Univ of Alabama at Birmingham (UAB) (workgroup member)

Lisa Suter, MD, Yale University (workgroup member)

Neil Wenger, MD, UCLA (panel moderator)

Martin Bergman, MD, private practice-Ridley Park, PA (panel member)

Harjinder Chowdhary, MD, William W Backus Hospital (panel member)

Fiona Donald, MD, Health Plan of San Mateo (panel member)

Jerome Epplin, MD, Litchfield Family Practice Center (panel member)

Danielle Jones, MD, Emory University School of Medicine (panel member)

Dinesh Khanna, MD, MSc, University of Michigan (panel member)

#2526 Gout: Anti-inflammatory Prophylaxis with ULT Therapy (Not Recommended for eMeasure Trial Approval), Last Updated: Oct 27, 2014

Michael Lazarus, MD, UCLA (panel member) Gerald Levy, MD, MBA, Kaiser Permanente (panel member) Tom Mattimore, MD, UCLA (panel member) David Mount, MD, Brigham and Women's Hospital (panel member) Ed Sims, Patient (panel member) John Sundy, MD, Duke University Medical Center (panel member)
<b>Measure Developer/Steward Updates and Ongoing Maintenance</b> <b>Ad.2 Year the measure was first released:</b> 2014 <b>Ad.3 Month and Year of most recent revision:</b> 02, 2014 <b>Ad.4 What is your frequency for review/update of this measure?</b> Annually, once the measure is fully tested and finalized <b>Ad.5 When is the next scheduled review/update for this measure?</b> 03, 2014
<b>Ad.6 Copyright statement:</b> N/A - measure is still being tested <b>Ad.7 Disclaimers:</b>
<b>Ad.8 Additional Information/Comments:</b>